BioWorld MedTech

April 25, 2012

Deals roundup: Orthofix sheds sports medicine unit to WSHP for $157 million

Orthofix (Lewisville, Texas) is narrowing its focus and concentrating more on the spine and orthopedics space with the news of it divesting its sports medicine business unit Breg (Carlsbag, California). Read More

FDLI Annual Conference: Hamburg: 2012 may prove to be 'a landmark year' for legislation

International report: VivaSight management platform to be marketed by Champ Medics

VeriStrat results correlate with lung cancer survival outcome

Financings roundup: HOOPP makes commitment to Klass Capital Fund I

HIT roundup: HITRUST helps heathcare avoid cyberattack threats

Agreements/contracts: JDRF partners with Dexcom for CGM smart transmitter

People in the News

Product Briefs

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 17, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

European Commission floats multiple fixes for MDR, IVDR

BioWorld MedTech

The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.